Shareholders and the investment community became concerned that Medexus Pharmaceuticals (MDP.T) would not be able to deal with the imminent expiry of convertible debentures the company had issued early in its existence to fuel its growth.
This concern grew into panic and Medexus shares took a serious hit, even though management were well aware of the situation and busy crafting solutions. Ken d’Entremont, CEO and director of Medexus, assured investors during a quarterly earnings call that the company was actively dealing with the issue, but doubt remained.
On March 8, 2023, Medexus announced it had secured a new debt facility with BMO that would not only provide the company sufficient gas to move forward, but also deal with the soon-to-be debentures without share dilution.
Equity Guru founder, Chris Parry, explains what Medexus has done, what it means for growth and why investors should be celebrating.
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Shareholders and the investment community became concerned that Medexus Pharmaceuticals (MDP.T) would not be able to deal with the imminent expiry of convertible debentures the company had issued early in its existence to fuel its growth.
This concern grew into panic and Medexus shares took a serious hit, even though management were well aware of the situation and busy crafting solutions. Ken d’Entremont, CEO and director of Medexus, assured investors during a quarterly earnings call that the company was actively dealing with the issue, but doubt remained.
On March 8, 2023, Medexus announced it had secured a new debt facility with BMO that would not only provide the company sufficient gas to move forward, but also deal with the soon-to-be debentures without share dilution.
Equity Guru founder, Chris Parry, explains what Medexus has done, what it means for growth and why investors should be celebrating.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
Medexus (MDP.T) CEO explains sudden drop
More on MDP.T
Medexus Pharmaceuticals’ (MDP.T) financials are coming!
Medexus Pharma (MDP.T) is an arbitrage in the making
Medexus Pharmaceuticals (MDP.T) building serious value
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E111
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023